Pfizer Inc

NYSE: PFE
$25.83
+$0.06 (+0.2%)
Closing Price on November 27, 2024

PFE Articles

Stock buybacks have come under more scrutiny by the public and politicians in recent years, but companies still aggressively are buying back shares of their own stock.
These five top stocks, all rated Buy at Merrill Lynch, come with outstanding dividends and have good growth prospects.
Gene therapy may become the next frontier for drug companies seeking to make billions of dollars improving or even curing certain diseases.
Pfizer is looking to collaborate with Vivet on the development of its proprietary treatment for Wilson disease.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with one major exception.
Judging by the most shorted stocks traded on the New York Stock Exchange between the February 15 and February 28 settlement dates, those sellers were cautious overall, as moves were mixed and...
The February 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Judging by the most shorted stocks traded on the New York Stock Exchange between the January 31 and February 15 settlement dates, those sellers were shifting priorities, as moves were mixed with some...
The top analyst upgrades, downgrades and initiations seen for Monday included Allscripts Healthcare Solutions, AmeriGas Partners, CVS Health, IMAX, Kraft Heinz, Marathon Oil, Microsoft and Pfizer.
The January 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
There are many stocks that are targeted toward mature adults and seniors or that offer classical investing themes for those who are retired now or are within a decade of retiring.
These four solid companies have released good earnings and pay consistent and healthy dividends. All make more sense going forward for investors getting a little nervous about what the rest of 2019...
The top analyst upgrades, downgrades and initiations seen on Thursday included Allergan, Boeing, Facebook, GoPro, Microsoft, Pfizer, Royal Dutch Shell, ServiceNow and Tiffany.
There is great opportunity in healthcare. There is also quite a lot of risk. Politicians and consumers alike want lower drug prices. Patients want the best of the best options for devices,...
Pfizer released better-than-expected fourth-quarter financial results and guidance before the markets opened on Tuesday.